FDA Pushing Forward With Withdrawal Of Two Concerta Generics
Executive Summary
Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.
You may also be interested in...
Amylyx’s ALS Pledge Vs. FDA’s Obscure Withdrawal Authority: Which Holds More Power?
Office of Neuroscience Director Billy Dunn touted FDA’s ability to withdraw approval for AMX0035 if subsequent data indicate a lack of substantial evidence of effectiveness. However, this provision appears to have been infrequently used and involves a potentially time-consuming hearing.
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.
Generic Drug Surveillance Could Be Enhanced By Dispensers Recording NDC, Manufacturer Data
US FDA’s MedWatch program could benefit from additional data capture – and generic and biosimilar reputations could too.